The RECOVERY trial: cardiovascular implications of a large, simple randomized trial in COVID-19.

Pessoa-Amorim, Guilherme; Mafham, Marion M

Pessoa-Amorim, Guilherme; Mafham, Marion M.

Pessoa-Amorim G; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK.
Mafham MM; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK.

Cardiovasc Res ; 117(9): e110-e113, 2021 07 27.

Article in English | MEDLINE | ID: covidwho-1328916

Subject(s)

Anti-Inflammatory Agents/therapeutic use; Antiviral Agents/therapeutic use; COVID-19 Drug Treatment; Cardiovascular Diseases/drug therapy; Fibrinolytic Agents/therapeutic use; Aged; Anti-Inflammatory Agents/adverse effects; Antiviral Agents/adverse effects; COVID-19/diagnosis; COVID-19/mortality; Cardiovascular Diseases/diagnosis; Cardiovascular Diseases/mortality; Cause of Death; Female; Fibrinolytic Agents/adverse effects; Heart Disease Risk Factors; Humans; Male; Middle Aged; Research Design; Risk Assessment; Time Factors; Treatment Outcome

Keywords

Antithrombotic; Antiviral; COVID-19; Immunomodulation; Randomized trial

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Cardiovascular Diseases / Fibrinolytic Agents / COVID-19 Drug Treatment / Anti-Inflammatory Agents Type of study: Diagnostic study / Experimental Studies / Prognostic study / Randomized controlled trials Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Cardiovasc Res Year: 2021 Document Type: Article Affiliation country: Cvr

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google